REBTX

Integrative strategy for the development of urinary bladder analogs

Coordinatore	STICHTING KATHOLIEKE UNIVERSITEIT    more  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Wim Cognome: Van Oijen Email: send email Telefono: +31 243618937
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	183˙469 €
EC contributo	183˙469 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IEF
Funding Scheme	MC-IEF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-03-01   -   2016-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Wim Cognome: Van Oijen Email: send email Telefono: +31 243618937	NL (NIJMEGEN)	coordinator	183˙469.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

The current treatment of bladder defects is often associated with high site morbidity and patient discomfort. The therapeutic standard methods, involve the use of materials with low biological performance and lack in replicating the bladder’s anatomical structure. Regenerative Bladder Therapy (ReBTx) aims in addressing the reconstruction of the bladder by using an innovative bottom-up approach, to recreate the physiology of the bladder tissue. In a first stage, a 3D network based on a functionalized hydrogel will be developed to allow the cellular growth and protrusion of blood vessels. Then, the optimized gel, with or without cells, will be incorporated within a porous collagen-based scaffold that will offer mechanical support and guidance for tissue regeneration. The ReBTx constructs will be tested in in vivo settings to properly evaluate the construct integration, recruitment of blood vessels and function acquisition. The transition from fundamental research (in vitro optimization) towards clinical application (in vivo) will render the possibility to address the complex mechanism involved in bladder regeneration. The potential towards patenting and commercialization will be closely taken under consideration, due to the bench-to-bed side aspect of the ReBTx proposal and the intimate collaboration between several high ranked groups at Radboud University (NL) and entrepreneurial entities (NovioTech, BV and EMCM, BV, NL). Eventually, ReBTx could be implemented to significantly improve the patients’ quality of life. The multi-facetted sides of the ReBTx approach enable the use and acquisition of an extensive knowledge and experience in tissue engineering concepts, equipping the applicant with solid managerial, social, and scientific skills that will pave the path towards the development of a scientific career. Even more, the use of a clinical setup will equip the candidate with practical and conceptual tools for translational aspects of tissue engineering.